30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Histogenics' Top-Line Results From Phase 3 Trial of NeoCart -

Histogenics' Phase III clinical trial of NeoCart® tissue engineered implant did not meet the primary endpoint of a statistically significant improvement in pain and function vs. microfracture in a dual threshold responder analysis at one year. In the modified Intent to Treat (mITT) population (which excludes patients who were randomized but not treated with NeoCart), 74% of NeoCart patients exhibited clinically meaningful improvements in pain and function vs. 62% of microfracture patients. However, in this mITT population, patients treated with NeoCart achieved a statistically significant improvement in pain and function at six months vs. microfracture. (Histogenics Corporation, 9/5/18)